with our second generation technologies.
Progressed our preclinical programs in regenerative therapeutics,
neurodegenerative disease and molecular imaging.
-- Data from a rodent study designed to measure the levels of Inosine in
the brain during intravenous infusion of high concentrations of Inosine
were presented at the American Society for Experimental
NeuroTherapeutics (ASENT). This study showed that, when administered
intravenously using a new, high concentration formulation of Inosine,
Inosine levels in the brain increased more than 600% over baseline
levels. Inosine is a nerve regenerative factor that has been shown to
promote axon outgrowth in neurons and has potential to be used to treat
CNS disorders such as spinal cord injury, stroke, and traumatic brain
-- Findings from a study to determine brain bioavailability following oral
administration of three of Alseres' highly-selective dopamine
transporter (DAT) blockers were also presented at the ASENT meeting.
The data presented showed that all three of the Company's DAT blockers
given orally were rapidly absorbed into the blood and the brain and
provided favorable brain-to-blood plasma ratios.
-- Working with our scientific collaborators, we initiated a series of
comparative studies in which other of our regenerative technologies,
including Inosine, Oncomodulin and other compounds, are being tested in
parallel in a series of models of CNS disorders to assess their
potential to enhance nerve repair. If successful, these studies may
enable the most promising candidates and indications to be taken
forward in development.
-- We are also evaluating our Rho inhibitors in animal models to assess
their ability to stimulate cells to regenerate bone. It is estimate
|SOURCE Alseres Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved